McKesson is a massive healthcare company that distributes one-third of all pharmaceutical drugs in North America. The business reached $403.43 billion in revenue in the fiscal year ended March 31, 2026, growing 12% over the prior year. It operates as the critical middleman between drug manufacturers and pharmacies, hospitals, and clinics.
The investment thesis on McKesson is that its specialty pharmaceutical and oncology platforms are transforming it from a low-margin delivery business into a higher-margin healthcare services provider. While the core business moves boxes of pills for tiny fees, its expansion into complex specialty drugs and cancer care management offers much better profit potential. If it continues to shift its mix toward these services, earnings should compound faster than revenue.
We think McKesson is a well-managed giant that is effectively using its scale to move into more profitable corners of the healthcare market. The thesis breaks if regulatory changes sharply compress the fees it earns for drug distribution.
McKesson's stock price soared over the last five years but has dipped recently as investors take a breather. The company acts as a giant middleman that delivers most of our medicine. It is now trying to make more money by providing specialized cancer care and services instead of just moving boxes of pills from place to place.
What does it do?
McKesson is a mature business that earns money by sourcing, distributing, and managing the supply chain for pharmaceutical and medical products. The company acts as a vital bridge between drug manufacturers and healthcare providers like retail pharmacies, hospitals, and oncology clinics. It buys drugs in massive bulk and distributes them through a highly automated network, earning a small fee on every unit that passes through its system. Beyond simple delivery, it provides software to pharmacies to help them manage their businesses and specialty services for complex treatments like cancer therapy.
Where does revenue come from?
The vast majority of revenue comes from distributing pharmaceutical drugs to retail national accounts and independent pharmacies. The U.S. Pharmaceutical segment is the engine, followed by Medical-Surgical Solutions, which provides supplies like gloves and bandages to doctors' offices. Prescription Technology Solutions offers software for managing drug costs and adherence, while the International segment covers its remaining operations outside the United States.
Revenue Breakdown
Revenue by Geography
Who are its customers?
McKesson serves thousands of retail pharmacies, hospital networks, and independent physician practices across the globe. Its largest customers include retail giants like CVS Health and Rite Aid, as well as thousands of independent community pharmacies that rely on McKesson for daily drug shipments. In its oncology business, it serves thousands of providers through its The US Oncology Network, which helps independent cancer clinics manage their clinical and financial operations. The company also handles specialty distribution for manufacturers of complex biologics and orphan drugs.
What gives it staying power?
The business has staying power because its massive distribution network creates a cost advantage that is nearly impossible for new competitors to replicate. It would cost billions of dollars and take decades to build the warehouses and delivery routes required to move one-third of North America's pharmaceutical supply.
Where is it headed?
McKesson is focusing its future on expanding its specialty healthcare and oncology platforms to capture higher margins. Management is doubling down on services for oncology clinics and biopharma companies, moving beyond just shipping boxes to providing the software and clinical data that help doctors treat complex diseases more effectively.
Revenue grew 12% last year to reach $403.43 billion, reflecting a business that is still expanding despite its massive size. The acceleration was primarily driven by higher prescription volumes and the continued ramp-up of its specialty drug distribution.
Cash generation is exceptional, with free cash flow of $5.72 billion representing more than 100% of net income. This high cash quality proves the business is efficient at turning its slim 1.2% net margins into real cash for shareholders.
The balance sheet is managed conservatively, allowing the company to sustain a 31.1% return on invested capital. While it carries debt to fund its massive inventory, its steady cash flows more than cover its interest and capital needs.
McKesson is a financially formidable giant that uses its massive scale and high capital efficiency to dominate a low-margin industry.
Return on invested capital reached 31.1%, proving the company is highly efficient at deploying its cash into profitable growth. This efficiency allows McKesson to generate billions in free cash flow even with net margins as low as 1.2%.
Regulatory changes to drug pricing models could compress the already thin margins McKesson earns on every pill delivered. If the government or private insurers change how distributors are paid for specialty drugs, the company's profit growth could stall.
The pharmaceutical distribution market is a $1 trillion global industry growing roughly 5% annually, on track to reach $1.3 trillion by 2028. This is an excellent industry for incumbents because high volume and razor-thin margins create a structural barrier to entry. Pricing power is limited by the concentrated power of pharmacies and manufacturers, but the sheer necessity of the service makes it highly stable. McKesson stands as one of the three dominant players in this market, controlling roughly a third of the distribution runway in North America.
This market is rationally structured as a triopoly where the top three players control the vast majority of volume. Barriers to entry are immense because the required logistics network and regulatory compliance are too costly for new entrants to build. This structure prevents a race to the bottom on price, as all players must maintain some margin to survive.
Cencora and Cardinal Health are the two main threats, constantly bidding against McKesson for large retail and hospital contracts. The most dangerous long-term threat is Amazon, which could use its existing logistics backbone to eventually bypass traditional distributors for medical supplies and common prescriptions.
McKesson is holding its ground and slowly gaining share in the high-value specialty and oncology markets. Its $403 billion in annual revenue is proof that its scale remains a decisive advantage.
The primary source of protection is efficient scale, which allows McKesson to move drugs at a lower cost per unit than almost anyone else. This cost advantage exists because the company has already paid for the massive warehouse and delivery network that a competitor would have to build from scratch. Its revenue of $403 billion gives it immense purchasing power with manufacturers.
The 31.1% ROIC is the single most compelling proof of a wide moat. These high returns in an industry with 3.6% gross margins prove that McKesson is not just a delivery company but a highly efficient capital recycler. The numbers are consistent with a real moat, as they have remained high even through various economic and regulatory cycles.
The moat is stable, with the shift toward specialty drugs and oncology software increasing switching costs for its best customers.
Raised full-year EPS guidance during FY2026 while maintaining 12% revenue growth.
Generated $5.72B in FCF and consistently returned cash through buybacks.
CEO holds a substantial stake and pay is tied to long-term returns.
Capital Allocation Track Record
Brian S. Tyler and his team have proven they can grow a massive business while maintaining discipline on costs and capital. Their strategic decision to exit retail businesses in Canada to focus on high-margin specialty healthcare shows a clear understanding of where the best returns are found. The 31.1% return on invested capital is a direct result of their ability to manage a thin-margin business with extreme precision.
The leadership risk is low, as McKesson has a deep bench of experienced executives and a clear, multi-year strategy. While the company is large, the thesis is driven by broad structural shifts in healthcare rather than the vision of a single founder. The board is independent and incentives are well-aligned with shareholders, prioritizing free cash flow and earnings per share growth.
We expect revenue to grow from $408B in FY2026 to $536B in FY2031 (~6% CAGR), with EPS growing from $39.01 to $71.52 (~13% CAGR). Growth is driven by the steady expansion of the specialty pharmaceutical market and increased distribution volume to oncology clinics. Profitability improves as the company shifts its mix toward high-margin specialty drugs and oncology services while maintaining a lean cost structure Operating margin expected to reach ~2% by FY2031.
Specialty drug volume grows as a share of total distribution. As manufacturers launch more complex biologics, McKesson’s high-margin specialty segment will become a larger contributor to overall profit.
Oncology platform expansion through new clinic acquisitions and software. Expanding the US Oncology Network creates higher switching costs and deeper data integration with healthcare providers.
Continued share count reduction through aggressive buybacks. Using billions in annual free cash flow to buy back shares will drive double-digit EPS growth even if revenue growth is more modest.
Regulatory changes to drug reimbursement models compress distribution fees. If the government or private insurers significantly lower what they pay for drug distribution, McKesson’s thin margins could vanish.
Competition from Amazon in medical supply and pharmacy distribution. Amazon using its superior logistics to win hospital and retail contracts could force McKesson to lower its prices to keep volume.
Supply chain disruptions for critical specialty pharmaceutical ingredients. Any major break in the global pharmaceutical supply chain would hit volumes and increase operating costs for the distribution network.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach based on next year's earnings power. This framework is the industry standard for healthcare distributors because their massive revenue scale and thin margins make price-to-sales ratios unhelpful, while their steady profitability and low capital intensity make earnings a highly reliable signal of value.
Our fair value of $974 is calculated by applying a 22x multiple to the FY2027 EPS estimate of $44.26. This 22x multiple sits at the high end of the peer range (Cencora at 21x and Cardinal Health at 17x), a premium we believe is justified by McKesson’s superior scale and its aggressive, successful integration of the US Oncology Network. Our EPS basis follows the deterministic projection for the next fiscal year, reflecting the 12-15% growth guidance recently raised by management.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $918 — within 6% of our Forward P/E answer of $974, confirming the result. Using a 9.0% discount rate and a 3% terminal growth rate, the DCF captures the long-term value of McKesson's shift toward high-margin technology and oncology services more granularly than a single-year multiple. The close alignment between the two frameworks suggests that our 22x forward multiple accurately reflects the market's expectation for durable, high-quality earnings growth.
We're assuming the Oncology and Multispecialty segment sustains double-digit revenue growth through FY2028. Recent acquisitions of PRISM Vision and Core Ventures, which added 3,300 providers to The US Oncology Network, support this trajectory as McKesson shifts away from lower-margin general distribution toward high-value specialty care.
We're assuming operating margins expand by approximately 20 basis points as the specialty mix increases. While the core pharmaceutical segment operates at razor-thin margins, the specialty and technology segments command significantly higher profitability; a shift in mix of just 2-3% of total revenue provides meaningful leverage to the bottom line.
We're assuming the partnership with CVS Health remains stable through at least June 2027. With CVS accounting for 27% of total revenue, the recently announced contract extension provides the cash flow visibility required to fund the company’s higher-growth technology and oncology bets.
The biggest risk is a structural change in pharmaceutical distribution if manufacturers move toward direct-to-pharmacy models for high-volume drugs. This would bypass McKesson’s core wholesale infrastructure, potentially compressing the forward multiple from 22x to 16x and knocking roughly $260 off the per-share fair value. Watch for announcements from major weight-loss or oncology drug manufacturers regarding proprietary pharmacy-direct shipping initiatives.
Bear case ($820): CVS Health (27% of revenue) announces intent to move distribution in-house or diversify to a competitor by June 2027; or Adjusted EPS growth for FY2027 falls below 8% due to sharper-than-expected price erosion in generic drugs.
Bull case ($1,150): The Oncology and Multispecialty segment grows to represent 15% of total revenue within 24 months, expanding consolidated margins; or Strategic investment in AI-powered suite of biopharma services results in a 150bps improvement in ROIC.
Clearthesis wrote this report from 35 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because McKesson is successfully evolving from a simple drug wholesaler into a higher-margin healthcare services provider. By expanding its oncology and specialty drug platforms, the company is capturing more profit from complex treatments beyond its traditional low-fee pill distribution business. This strategy is consistently driving revenue growth.
Skeptics think that relying on these new services ignores the heavy risks inherent in the massive underlying distribution business. The core operation still moves one-third of all North American drugs for very small fees, meaning any disruption to these immense volumes could quickly overwhelm gains from newer specialty segments.